



Boston Heart Diagnostics Reaches Agreement with DOJ to Resolve Legacy Claims

FRAMINGHAM, MASS., [November 26, 2019] – Boston Heart Diagnostics Corporation (“BHD”), a clinical diagnostics company specialized in advanced cardiovascular testing, announced today that it has reached an agreement to resolve all existing investigations by the U.S. Department of Justice (“DOJ”).

Since the original claims were made, BHD has assumed new leadership, including a new corporate owner, a new board of directors, a chief compliance officer and an experienced management team committed to compliance with all federal and state laws, regulations and rules.

“We are pleased to put behind us legacy issues relating to qui tam lawsuits dating in some respects as far back as 2012,” said Patrick Noland, BHD President since April 4, 2017. “Boston Heart is a very different organization today compared to what it was then and up to two and a half years ago.”

Under the terms of the agreement, Boston Heart, without admitting liability, has agreed to pay a civil monetary settlement of \$26.7 million to resolve all civil claims available to the U.S. government under the Federal False Claims Act (“FCA”). Importantly, there were no claims that individual patients were harmed as a result of the alleged conduct.

As part of the settlement, the Office of Inspector General (“OIG”) elected not to require a corporate integrity agreement (“CIA”), which speaks to BHD’s successful adoption and implementation of a highly functional and robust corporate compliance program.

“Compliance, innovation and quality are at the heart of our business and we are committed to being a leader in these areas,” Noland said. “We are proud of the work we do and remain dedicated to the treatment and prevention of disease by offering novel diagnostics that drive a personalized approach to improve patient health.”

CONTACT: Patrick Noland, President
(508) 739-4881 or PNoland@BostonHeartDx.com

About Boston Heart Diagnostics Corporation

Boston Heart Diagnostics (“BHD”), a subsidiary of Eurofins Scientific (EUFI.PA), is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve heart health. Boston Heart looks beyond the “good” and “bad” cholesterol assessment that conventional labs provide to give a more complete picture of heart health. For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com



508.877.8711

bostonheartdiagnostics.com